October 24, 2022
BONESUPPORT’s CERAMENT®G used in first U.S. patient cases
Media
October 20, 2022
Issue and re-purchase of class C shares for shareholder program and incentive program
October 20, 2022
The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info
October 12, 2022
Vicore selects new ATRAG as next Drug Candidate
October 06, 2022
Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study
October 05, 2022
The ONCOS-102 phase 1b melanoma study selected for oral presentation at the SITC 2022 annual meeting
October 04, 2022
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
October 03, 2022
Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market
September 27, 2022
Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA
September 23, 2022
Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC
